SCHEMBL1486643

SCHEMBL1486643

COCc1nc2cnc3cc(OCc4ccccc4)ccc3c2n1CCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.54
TSHR P16473 7/20 0.45
CYP1A2 P05177 5/20 0.45
ALDH1A1 P00352 4/20 0.45
CYP2C19 P33261 4/20 0.45
CYP2C9 P11712 3/20 0.45
CYP2D6 P10635 2/20 0.45
CYP3A4 P08684 5/20 0.43
USP2 O75604 2/20 0.43
CLK4 Q9HAZ1 1/20 0.43
TP53 P04637 5/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
HIF1A Q16665 1/20 0.41
KIT P10721 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1486493 0.85 CYP3A4 (0.43) TSHRCYP1A2ALDH1A1CYP2C19CYP2C9
SCHEMBL1486552 0.83 TLR7 (0.56) L3MBTL1
SCHEMBL4242695 0.83 TLR7 (0.41) TSHRCYP1A2ALDH1A1CYP2C19CYP2C9
SCHEMBL1486433 0.82 L3MBTL1 (0.50) L3MBTL1TSHRCYP1A2ALDH1A1CYP2C19
SCHEMBL4240323 0.81 TP53 (0.45) L3MBTL1TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL19968181 0.81 TLR7 (0.44)
SCHEMBL310769 0.80 CYP3A4 (0.41) TSHRCYP1A2ALDH1A1CYP2C19CYP2C9
SCHEMBL27640403 0.80 CYP3A4 (0.39) CYP3A4TP53MAPTRAB9ANPC1
SCHEMBL1486523 0.80 SMN1; SMN2 (0.47) TSHRALDH1A1TP53MAPTSMN1; SMN2
SCHEMBL1486760 0.79 TLR7 (0.43) L3MBTL1CYP1A2CYP2C19CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658076-B1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2013-03-06 EP disclosed
US-8263594-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-09-11 US disclosed
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2011-06-16 US disclosed
US-7897597-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
EP-1658076-A4 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2009-02-25 EP disclosed
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2009-01-15 US disclosed
EP-1658076-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2006-05-24 EP disclosed
WO-2005020999-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines IL2, IFNG, IRF3 L3MBTL1 3724/4885TSHR 1426/4885CYP1A2 1179/4885
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 L3MBTL1 3693/4885TSHR 1257/4885CYP1A2 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.